Michelle Morrow has left her position at Avacta to join Nucleome Therapeutics as Chief Scientific Officer (CSO). Morrow joins Nucleome with two decades of experience in drug discovery and development and executing R&D strategy across biotech and large pharma. Prior to Avacta, Michelle was SVP, Head of invoX Therapeutics Innovation, following its acquisition of F-star […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!